Analysis of N-glycans on vascular endothelial growth factor receptor-2 in diabetic retinopathy
Project/Area Number |
16K15728
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Ophthalmology
|
Research Institution | Hokkaido University |
Principal Investigator |
Ishida Susumu 北海道大学, 医学研究院, 教授 (10245558)
|
Co-Investigator(Kenkyū-buntansha) |
西村 紳一郎 北海道大学, 先端生命科学研究院, 教授 (00183898)
野田 航介 北海道大学, 医学研究院, 准教授 (90296666)
|
Project Period (FY) |
2016-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 血管内皮増殖因子受容体-2 / N型糖鎖 / 糖尿病網膜症 / 低酸素 / 糖鎖 / 眼細胞生物学 |
Outline of Final Research Achievements |
Vascular endothelial growth factor (VEGF), a potent angiogenic and vascular permeability factor, plays a significant role in the pathogenesis of diabetic retinopathy. In the current study, we analyzed the structures of N-glycans on the receptor of VEGF, VEGFR-2. On the basis of preexisting database for glycan structure, the 16 structures of N-glycans on VEGFR-2 were identified in human retinal microvascular endothelial cells (HRMECs). However, no alteration of N-glycans was found on VEGFR-2 in HRMECs cultured under hypoxic condition, one of the representative pathological condition in diabetic retinopathy, for 24 hours compared to that under normoxic condition.
|
Report
(3 results)
Research Products
(10 results)
-
-
[Journal Article] Phosphorylation of alphaB-crystallin in epiretinal membrane of human proliferative diabetic retinopathy.2016
Author(s)
Dong Y, Dong Z, Kase S, Ando R, Fukuhara J, Kinoshita S, Inafuku S, Tagawa Y, Ishizuka ET, Saito W, Murata M, Kanda A, Noda K, Ishida S
-
Journal Title
Int J Ophthalmol
Volume: 9
Pages: 1100-1105
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-